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A B S T R A C T
Purpose
The aim of this study was to examine the clinical effects of switching from transdermal (TTS)
fentanyl to methadone, or vice versa, in patients with a poor response to the previous opioid.
Patients and Methods
A prospective study was carried out on 31 patients who switched from TTS fentanyl to oral
methadone, or vice versa, because of poor opioid response. A fixed conversion ratio of
fentanyl to methadone of 1:20 was started and assisted by rescue doses of opioids, and then
doses were changed according to clinical response. Pain and symptom intensity, expressed
as distress score, were recorded before switching doses of the two opioids and after
subsequent doses. The number of changes of the daily doses, time to achieve stabilization,
and hospital stay were also recorded.
Results
Eighteen patients were switched from TTS fentanyl to methadone, and seven patients were
switched from methadone to TTS fentanyl. A significant decrease in pain and symptom
intensity, expressed as symptom distress score, was found within 24 hours after switching
took place in both directions. Unsuccessful switching occurred in six patients, who were
subsequently treated with an alternative therapy.
Conclusion
A rapid switching using an initial fixed ratio of fentanyl to methadone of 1:20 is an effective
method to improve the balance between analgesia and adverse effects in cancer patients
with poor response to the previous opioid. No relationship between the final opioid dose and
the dose of the previous opioid has been found.
J Clin Oncol 23:5229-5234. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Opioids are the mainstay of moderate to
severe cancer pain management. Although
morphine is usually considered the pre-
ferred drug for the treatment of severe can-
cer pain because of its wide availability,
varied formulations, and well-characterized
pharmacologic properties, fentanyl use has
been increasing in the last years. Previous ex-
periences have shown that a failure to respond
tooneopioiddoesnotmeanfailure torespond
to all opioids, and opioid switchingmay allow
better pain control and decrease the intensity
of adverse disabling effects.1-5
The keystone to the rationale behind
opioid substitution is incomplete cross tol-
erance, although the exact reason why opi-
oid substitution is successful remains
unclear. In some patients, poorly responsive
pain may arise because of the development
of analgesic tolerance to an opioid, whereas
tolerance to adverse effects does not develop
to the same extent. As a consequence, the
escalating dose of any opioid may reach a
level at which the adverse effects become
predominant. Thus, the benefit of a switch
from one opioid to another opioid could
depend on cross tolerance to the analgesic
effects being less than cross tolerance to the
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adverse effects. The disadvantage is that it is impossible to
know in advance if the balance between analgesia and ad-
verse effects will be more convenient after opioid substitu-
tion. In addition, the dose of the alternative opioid chosen
may be uncertain because it will depend on a series of
factors, including individual response, pain mechanism,
and degree of cross tolerance.6
Different modalities and conversion ratios have been
reported for switching to methadone. Each approach has a
rationale.2,4,7-9 Methadone is characterized by the risk of
accumulation because of its complex pharmacokinetics.10
Transdermal (TTS) fentanyl prescription is growing among
physicians, particularly in some countries. As a conse-
quence, alternative treatments are needed for patients not
responding to fentanyl. Methadone may be a useful alter-
native to improve opioid response. Although equianalgesic
conversion ratios between morphine and fentanyl have
been established in previous studies, data are lacking about
the conversion ratio between fentanyl andmethadone, par-
ticularly in the setting of a poor opioid response. The aim of
this study was to evaluate a protocol of rapid substitution of
TTS fentanyl withmethadone, or vice versa, using an initial
ratio of fentanyl to methadone of 1:20 in patients with a
poor opioid response and then modifying the dose accord-
ing to clinical effects in an intensive setting of palliative care.
PATIENTS AND METHODS
A prospective study was carried out in a sample of consecutive
patients admitted in an acute palliative care unit for a period of 1
year. Informed consent and institutional approval were obtained.
Thirty-one consecutive advanced cancer patients receiving TTS
fentanyl or methadone who were required to switch opioid ther-
apy because of an inconvenient balance between analgesia and
adverse effects were included in the study. Patients with a poor
analgesic response, despite having their dose doubled in 1 week,
were also included.
The following protocol was used. The patients were switched
using a fentanyl to methadone ratio of 1:20. The daily dose calcu-
lated of methadone was divided into three doses daily, and a
further dose of one sixth of the daily dose was provided as needed.
Intravenous route was used when the oral tract was unavailable.
Fentanyl patches were removed with the first dose of methadone.
The same reciprocal ratio (20:1) was used for switching from
methadone to fentanyl. Similarly, in patients who were switched
from oral methadone to TTS fentanyl, the patch was applied
immediately after the last dose of methadone. Rescue doses of oral
or intravenous morphine, using the equivalent of one sixth of the
daily dose, were provided. The daily dose was changed according
to the clinical needs. When the dose calculated was not equivalent
to a standard patch, the difference was provided as equivalent
doses of continuous intravenous fentanyl.10 Each day, the sum of
all opioids administered was calculated, also taking into ac-
count the route of administration of rescue doses. The number
of changes in the planned daily doses, the time to reach a stable
daily dose (considered as the first of 2 consecutive days requir-
ing no more than two rescue doses), and time to hospital
discharge were recorded.
According to department policy, the conversion ratios used
among opioids and routes of administration, based on known
drug availability for oral, TTS, and intravenous routes of
administration,11-16 were the following: oral morphine 100 
intravenous morphine 33 TTS fentanyl 1 intravenous fenta-
nyl 1 oral methadone 20 intravenous methadone 16.
Adjuvant drugs that had been previously administered to
control symptoms caused by illness or treatment were continued
at the same doses during the switching. Nonopioid analgesics were
also continued, if previously administered, at the same doses. No
patient received anticancer therapy during the course of the study.
All patients were strictly monitored with frequent rounds by a
team consisting of doctors and nurses experienced in palliative
care. Daily doses were changed, according the amount of drugs
consumed as rescue doses in the previous day and clinical
judgement, to achieve an acceptable analgesia with minimal
adverse effects.
The following data were also recorded before switching and
after switching until hospital discharge: age; sex; primary cancer
and knownmetastases; pain causes andmechanisms; performance
status; preswitching opioid doses; daily opioid consumption, in-
cluding the planned daily dose and rescue doses; daily opioid doses
at time of stabilization; symptoms associated with opioid therapy
or commonly present in advanced cancer patients, such as nausea
and vomiting, drowsiness, confusion, constipation, dry mouth,
and so on, using a scale from 0 to 3 (not at all, slight, a lot, and
awful; symptoms were assessed by the patient, and the distress
score was calculated from the sum of symptom intensity); pain
intensity (measured using the patient’s self report on a numer-
ical scale of 0 to 10); and pain syndromes, which were consid-
ered on the basis of clinical history, anatomic site of primary
tumor and knownmetastases, physical examination, and inves-
tigations when available.
A successful switching was considered when the intensity of
pain and/or distress score (the reasons for switching) decreased by
at least 33% of the basal value recorded before switching, within
a reasonable period of time (commonly 4 to 7 days). Dose
stabilization was considered as the planned daily dose requiring
no more than two rescue doses. The first of 2 days with a stable
dose was considered as time of stabilization. Unsuccessful
switching was followed by alternative measures, including in-
trathecal therapy or a further switching to another opioid,
according to department policy.
Statistical Analysis
Frequency analysis was performed with the 2 test. The
pairedWilcoxon signed rank test was used to compare pain inten-
sity scores and symptom intensity scores in the time periods. The
paired samples Student’s t test was used to compare opioid mean
dose in the time periods. The one-way analysis of variance and
Mann-WhitneyU statistic test were used for parametric and non-
parametric analysis, respectively. All P values were two sided, and
P .05 was considered statistically significant.
RESULTS
The characteristics of patients are listed in Table 1. Twenty-
four patients were switched from TTS fentanyl to oral
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methadone, and seven patients were switched from oral
methadone to TTS fentanyl. The reasons for switching from
fentanyl to methadone were both adverse effects and poor
pain control, despite escalating opioid doses, in 14 patients,
poor pain control in four patients, and adverse effects in
four patients. The reasons for switching frommethadone to
fentanyl were both adverse effects and poor pain control in
five patients, poor pain control in one patient, and adverse
effects in one patient.
Themean preswitching TTS fentanyl daily dose was 4.2
mg/d (equivalent to 420 mg of oral morphine). According
to the initial ratio chosen (1:20), this group of patients
received an initial daily dose of oralmethadone of 84mg.Of
these 24 patients, 20 were receiving TTS fentanyl doses
 1.8 mg/d (equivalent to a relatively high dose of oral
morphine of approximately 180 mg/d), and four patients
were receiving doses less than 1.8 mg/d. Seven patients
receiving a mean daily dose of oral methadone of 30.8 mg
(equivalent to 154mg of oral morphine) were switched to a
mean initial daily dose of TTS fentanyl of 1.54 mg (Tables 2
and 3). Adjuvant agents used included the following: non-
steroidal anti-inflammatory drugs (n  17), laxatives
(senna, n  15; lactulose, n  10), gastroprotectors
(n  15), metoclopramide (n  10), haloperidol (n  6),
amitriptyline (n 4), corticosteroids (n 3), and ondan-
setron and carbamazepine (n 2).
Eighteen patients benefited from switching, improving
the balance between analgesia and adverse effects, as con-
firmed by the significant changes in the pain intensity and
distress score, even 24 hours after switching took place. At
hospital discharge, there was a mean reduction in pain
intensity and distress score of more than 33% of basal
(preswitching) data. The benefit of switching was observed
within 24 to 36 hours (Table 2 and 3). No significant differ-
ences between patients who switched because of poor pain
control and those who switched because of both poor pain
control and adverse effects were observed.
This clinical improvement was observed for both
switching directions. In the patients who switched from
TTS fentanyl to oral methadone, themean time to achieve a
daily dose stabilization after switchingwas 4.3 days, whereas
the mean time was 2 days in patients who switched from
oral methadone to TTS fentanyl; and the number of dose
changes required was 3.4 and 0.7 in the two switching
directions, respectively. Time to hospital discharge after
switching was 5.3 and 4.1 days for the patients who
switched from TTS fentanyl to oral methadone and vice
versa, respectively.
The mean number of rescue doses in the patients who
switched from TTS fentanyl to oral methadone and vice
versa during the hospital admission was 1.8 and 2.1 per day,
respectively. There were minimal differences (not statisti-
cally relevant) between the initial doses calculated and the
daily doses at the time of stabilization (15%when switching
from fentanyl tomethadone, and 30%when switching from
methadone to fentanyl; Tables 1 and 2).
In six patients who switched from TTS fentanyl to oral
methadone, the treatment was considered unsuccessful.
Table 1. Age, Sex, Number of Dose Changes, Time to Achieve a







Mean SE Mean SE




No. of changes of daily dose 3.39 0.31 0.71 0.42
Time to achieve stabilization, days 4.3 0.33 2.0 0.49
Time to discharge after switching, days 5.3 0.71 4.1 0.63
Table 2. Data of 18 Patients Who Completed the Switch From Fentanyl to Methadone Successfully
Measure
Day 0 Day 1 Day 2 Day 3 Day of Stabilization
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
No. of patients 18 18 18 17 18
Symptom
Pain 5.9 5.0 to 6.9 3.3 2.3 to 4.3 2.7 2.1 to 3.4 2.6 1.6 to 3.7 1.8 1.2 to 2.5
Nausea 0.9 0.3 to 1.5 0.4 0.0 to 0.9 0.3 0.0 to 0.6 0.3 0.0 to 0.6 0.3 0.0 to 0.5
Drowsiness 1.6 1.2 to 1.9 1.1 0.7 to 1.4 1.1 0.8 to 1.3 1.1 0.7 to 1.4 0.8 0.5 to 1.1
Confusion 0.5 0.1 to 0.9 0.3 0.1 to 0.6 0.1 0.0 to 0.3 0.3 0.1 to 0.6 0.3 0.1 to 0.6
Constipation 2.0 1.1 to 2.8 1.6 0.8 to 2.4 1.3 0.7 to 1.9 1.2 0.5 to 1.8 1.1 0.5 to 1.7
Dry mouth 1.2 0.7 to 1.6 0.9 0.6 to 1.3 1.0 0.6 to 1.5 1.0 0.5 to 1.6 0.8 0.4 to 1.1
Distress score 6.5 5.3 to 7.7 4.8 3.3 to 6.2 3.9 3.0 to 4.8 3.9 2.7 to 5.2 3.3 2.2 to 4.3
Methadone dose, mg/d 84 52 to 115 94 49 to 139 92 50 to 135 89 52 to 126 71 33 to 109
NOTE. See text for symptom scoring.
P  .05 compared with day 0.
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Data regarding these patients are listed in Table 4. These
patients received multiple changes in doses to obtain the
best balance between analgesia and adverse effects within 4
to 7 days. Three patients underwent a successful intraspinal
treatment with a combination of intrathecal morphine and
local anesthetics. One patient, whowas switched for adverse
effects, preferred to go back to fentanyl therapy. In two
patients, switching was not able to relieve a global state of
suffering (characterized by confusion, drowsiness, and oli-
guria), whichwas attributed to a terminal state and required
sedation with an intravenous midazolam-morphine com-
bination until death, which occurred on days 15 and 7.
DISCUSSION
The opioid switching between fentanyl andmethadone was
successful, in both directions, in approximately 80% of
patients (25 of 31 patients) using an initial conversion ratio
of 1:20 and a stop and go approach (regardless of the dose of
the previous opioid) and then modifying the dose of the
alternative opioid according to a flexible protocol and de-
pending on the clinical response. This ratio was relatively
maintained at time of stabilization, which was achieved
within 2 to 4 days, although it required frequent therapeutic
interventions during a mean of 4 to 5 days of admission to
achieve a timely equilibrium between analgesia and adverse
effects. This intensive approach was safe in an intensive
setting and allowed for a relatively short time admission.
Data regarding switching from other opioids to fenta-
nyl in unstable patients are lacking, probably because of the
unreliable pharmacokinetics of TTS fentanyl. Previous
studies performed using a subcutaneous infusion of fenta-
nyl in patients unresponsive to previous opioids suggest
similar conversion ratios when using morphine as an inter-
mediate conversion drug.17 Data on conversion from fent-
anyl to methadone or vice versa in the raw clinical setting
Table 3. Data of Seven Patients Who Completed the Switch From Methadone to Fentanyl Successfully
Measure
Day 0 Day 1 Day 2 Day 3 Day of Stabilization
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
No. of patients 7 7 7 5 7
Symptom
Pain 5.8 4.1 to 7.6 2.7 1.0 to 4.4 2.6 1.2 to 3.9 3.2 2.1 to 4.2 2.6 1.5 to 3.6
Nausea 1.8 0.7 to 2.9 1.3 0.2 to 2.3 1.4 0.2 to 2.6 1.4 0.3 to 2.5 1.6 0.2 to 2.9
Drowsiness 1.7 1.3 to 2.2 1.3 0.8 to 1.7 1.4 0.9 to 1.9 1.4 0.7 to 2.1 1.1 0.8 to 1.5
Confusion 1.4 0.9 to 1.9 0.7 0.2 to 1.2 0.0 0.0 0.4 0.3 to 1.1 0.1 0.2 to 0.5
Constipation 1.7 0.0 to 3.4 1.4 0.6 to 3.5 0.7 0.7 to 2.1 0.4 0.3 to 1.1 0.9 0.3 to 1.9
Dry mouth 2.2 1.1 to 3.2 1.7 0.8 to 2.6 2.0 1.2 to 2.7 1.4 0.3 to 2.5 2.1 1.1 to 3.1
Distress score 10.7 7.4 to 14.0 7.1 3.4 to 10.8 6.1 3.8 to 8.4 5.4 3.5 to 7.2 6.1 3.1 to 9.1
Fentanyl dose, mg/d 1.54 0.49 to 2.6 1.71 0.67 to 2.75 2.15 0.46 to 3.83 3.50 1.48 to 8.49 2.20 0.46 to 3.94
NOTE. See text for symptom scoring.
P  .05 compared with day 0.
Table 4. Data of Six Patients Who Switched From Fentanyl to Methadone Unsuccessfully
Measure
Day 0 Day 2 Day 2 Day 3 Last Day
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
No. of patients 6 6 6 6 6
Symptom
Pain 5.8 3.8 to 7.9 4.2 2.9 to 5.4 3.7 1.9 to 5.4 4.0 3.1 to 4.9 3.3 1.1 to 5.6
Nausea 1.5 0.1 to 2.9 1.5 0.1 to 2.9 1.0 0.3 to 2.3 0.8 0.4 to 2.1 0.0 0.0
Drowsiness 2.0 2.0 1.5 0.9 to 2.1 1.3 0.5 to 2.2 1.7 1.1 to 2.2 1.7 1.1 to 2.2
Confusion 0.8 0.1 to 1.6 0.5 0.0 to 1.1 0.5 0.0 to 1.1 0.3 0.2 to 0.9 0.8 0.1 to 1.6
Constipation 0.7 0.1 to 1.2 0.5 0.3 to 1.4 0.7 0.6 to 1.9 1.0 0.3 to 1.7 1.7 0.4 to 3.7
Dry mouth 1.3 0.2 to 2.4 1.2 0.1 to 2.2 1.0 0.1 to 2.1 0.8 0.4 to 2.1 1.3 0.5 to 2.2
Distress score 6.8 4.2 to 9.4 5.5 2.9 to 8.1 4.8† 2.2 to 7.4 4.8† 2.5 to 7.2 5.5 3.0 to 7.9
Methadone dose, mg/d 85 41 to 211 74 19 to 129 81 36 to 126 90 46 to 134 124 37 to 285
NOTE. See text for symptom scoring.
Last day corresponds to the day when alternative treatment was started.
†P  .05 compared with day 0.
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are even more rare in the literature. In a recent experi-
ence, a similar initial conversion ratio between TTS fen-
tanyl and oral methadone was used.18 However, the ratio
was used in a different protocol that postponed the ad-
ministration of methadone from 8 to 24 hours after
removing the patch, according to the dose of fentanyl.
There are no pharmacokinetic data supporting this ap-
proach because elimination curves of fentanyl after re-
moving the patch are similar, independent of the dose.
However, methadone has a high distribution volume,
and the first doses are unlikely to produce effective
plasma concentration because of its body disposition, so
the risk of overdose is unlikely, even though fentanyl
concentration slowly decays. This is exactly what hap-
pens at induction with TTS fentanyl when the last admin-
istration of a long-acting opioid (for example, slow-
release morphine) is usually administered at the same
time as patch application.
In the protocol proposed by Benitez-Rosario et al,18
patients who are switched for uncontrolled pain, despite
receiving high doses of fentanyl, could potentially have an
uncovered period of 12 to 24 hours in which their critical
conditions are likely to worsen, producing a sort of iatro-
genic therapeutic window (ie, a lowering of plasma opioid
concentration). Although data on time of stabilization are
reported, no data on these crucial first days after switching
were provided. The slow decay of fentanyl concentration
after removing the patch could correspond in some way to
the typical pharmacokinetic delay in increasing blood con-
centration of methadone during the first 12 to 24 hours.
Moreover, methadone doses were changed every 72 hours,
and this approach could produce a further delay in achiev-
ing the study goal and, thus, prolong the patient’s suffering.
The rationale of the approach used in the present study
was based on previous experiences, in which a priming dose
of methadone was considered necessary to obtain a rapid
outcome in an acute clinical setting, such as poor pain
control frequently associated with distressing opioid-
induced adverse effects, and in which rescue doses were
administered according to the clinical need.7 This ap-
proach, which is possible in an intensive setting where pa-
tients are strictly monitored, provides a basis to shorten
time to achieve stabilization and avoid prolonged distress in
patients with high levels of pain or symptomburden, even if
that means receiving relatively large doses of opioids after
switching. Other modalities have been shown to achieve
stabilization within prolonged and, sometimes, unaccept-
able periods of time.9
Some changes have been found between the calculated
initial dose and final doses used at time of stabilization,
depending on the direction of switching. When switching
from fentanyl to methadone, the final doses were approxi-
mately 15% lower than the doses calculated when using an
initial conversion ratio of fentanyl to methadone of 1:20
(from an initial calculated mean daily dose of 84 mg of oral
methadone to a final daily dose of 71 mg), whereas approx-
imately 30% higher final doses of fentanyl were adminis-
tered when switching frommethadone to fentanyl (from an
initial daily dose of TTS fentanyl of 1.54mg to a final dose of
2.20 mg). This means that doses of methadone will be
somewhat lower in the first switch direction and fentanyl
doses will be higher in the second switch direction com-
pared with the initial ratio chosen (fentanyl to methadone
ratios of 1:17 and 1:13, respectively, from an initial ratio of
1:20). This occurred independently of the preswitching opi-
oid dose. A similar observation was reported in a previous
study, where the final ratio between fentanyl and metha-
done was less than 1:20 (1:17).18 Despite being more com-
plicated, presumably this approach allowed for rapid
symptom control, as inferred by the early improvement
immediately observed in the first days after switching and
by the quick stabilization time, which was reached within a
mean of 4 days.
A lower number of patients were switched frommeth-
adone to fentanyl. This reflects the higher number of pa-
tients receiving TTS fentanyl, which is the opioid more
frequently used in Italy, compared with oral methadone.
Patients who switched to fentanyl required fewer changes in
daily doses, and time of stabilization was shorter. This ob-
servation can be explained by the type of drug delivery,
which does not allow frequent changes. The simultaneous
administration of intravenous fentanyl allowed us to
change the size of the patch when the doses required were
consistent in the range of the new patch dose. In contrast to
other studies, which reported a complex switching from
methadone to other opioids,19 switching to fentanyl was
equally effective.
Because, in some patients, it is often necessary to use
more than one route of administration during switching
(for example, in the presence of nausea and vomiting for
methadone) or to support a slow route (such as the TTS
route), it is important tomanage conversion ratios between
different routes of administration, other than among opi-
oids. Conversion ratios used in this study were based on
pharmacokinetic data concerning opioid availability with
different routes. In a previous study, a conversion ratio of
0.6 mg/d of intravenous fentanyl to 2.4 mg/d of methadone
(1:4) was used when substituting intravenous methadone
for intravenous fentanyl to calculate the initial dose of
methadone in advanced cancer patients with uncontrolled
pain and central adverse effects, such as drowsiness and
confusion.20 Given that the TTS to intravenous ratio for
fentanyl is equal to 1 (see Kornick et al21) and the intrave-
nous to oral ratio for methadone is 0.8, according to oral
methadone availability (although a ratio of 0.5 has often
been used),11,22 the large differences reported in conversion
ratios between the two routes (TTS fentanyl to oral metha-
done ratio of 1:20 v intravenous fentanyl to intravenous
Fentanyl and Methadone in Cancer Patients
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methadone ratio of 1:4) can be explained by the need to
strongly increase the opioid dose in specific clinical circum-
stances of uncontrolled pain.
No differences were found when considering the rea-
sons for switching. However, this could be attributed to the
low number of patients presenting different indications (ie,
both poor pain control and adverse effects, poor pain con-
trol, or adverse effects). Other limitations of this study
reflect those limitations that are well known in palliative
care research that is performed in patients in critical condi-
tions that can be difficult to control in a complex context,
such as patients with poor pain relief and/or severe adverse
effects, which require extreme efforts to improve the bal-
ance between analgesia and adverse effect as early as possi-
ble. Thus, this data should be considered as preliminary and
needs to be confirmed by larger experience. The approach
used in this study requires expertise and strict surveillance
in an acute setting, where symptom monitoring and con-
tinuous evaluation is the basis to maintain a high level of
safety while providing timely symptom control. It is possi-
ble that this approach cannot be extended to other settings.
However, the approach to these kinds of patients with rele-
vant clinical problems requires high-level facilities.
In conclusion, when switching between fentanyl and
methadone, the use of an initial ratio of 1:20, when stopping
the first drug and initiating the second one, resulted in a
clinical improvement in approximately 80% of patients,
independently of the dose and direction of switching. Nev-
ertheless, patients should be carefully monitored on an
individual basis for possible unexpected responses until
they achieve a clinical stabilization.
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